ValiRx PLC Posting of Annual Report and Notice of AGM (2395X)
30 Abril 2021 - 6:00AM
UK Regulatory
TIDMVAL
RNS Number : 2395X
ValiRx PLC
30 April 2021
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Posting of Annual Report and Notice of AGM
AGM Arrangements During Pandemic
Q&A after AGM
London, UK, 30 April 2021: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company announces its Annual Report and
Accounts for the year ended 31 December 2020 is available on the
Company's website, www.valirx.com and will shortly be posted to
relevant registered shareholders.
The Company also advises that the Notice of Annual General
Meeting (the "Notice") and Form of Proxy are also available on the
Company's website, www.valirx.com , and will shortly be posted to
registered shareholders. The Annual General Meeting will be held at
11:00 am on 27 May 2021.
- COVID-19 restrictions
Given the current Government advice on lockdown restrictions
associated with the pandemic, the Company has determined that the
resolutions to be voted at the AGM shall be voted on through a poll
rather than on the show of hands. The Company believes this is the
best and fairest way to ensure that the votes of all shareholders
can be taken into account, whilst also preventing the Company and
shareholders breaching applicable regulations. Accordingly, the
Company strongly encourages all shareholders to either submit their
proxy form or to use the CREST Proxy Voting Service, rather than
attend the meeting in person in accordance with the Company's
articles of association. Whilst completion and return of the proxy
form or using the CREST Proxy Voting Service would not preclude
shareholders from attending, speaking or voting in person at the
AGM should they so wish, shareholders are reminded that to do so
would potentially be in breach of UK Government regulations in
relation to the containment and control of COVID-19.
- AGM quorum to be constituted by minimum quorum of director-shareholders
The Board intends for the AGM to be held by a minimum quorum
constituted by shareholders who are also directors, or their
proxies, and shareholders are requested not to attend the AGM in
person.
The latest date for receipt of proxies is Tuesday 25 May 2021 at
11am in accordance with the procedure set forth in the Notice. The
result of the proxy votes will be announced after the AGM in the
usual way.
- Live virtual Q&A
In light of the inability to hold an in-person AGM for all
shareholders, the Chairman and the CEO will be holding an online
Q&A event for all shareholders at 1pm on 27 May 2021 after the
closing of the AGM. Shareholders will be required to pre-register
for this meeting and will be able to submit questions for a
subsequent interactive discussion. Full details of how to register
and access the event are available
https://www.valirx.com/shareholder-communications.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzy Dilly, Chief Executive suzanne.dilly @valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray/Jo Turner/Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469 0930
Duncan Vasey/Lucy Williams/Eran Zucker
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOADKKBKKBKDAQN
(END) Dow Jones Newswires
April 30, 2021 07:00 ET (11:00 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024